华海药业(600521.SH)：马来酸氟伏沙明片获得药品注册证书

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration of Fluoxetine Maleate Tablets, which are used to treat depression and obsessive-compulsive disorder [1] Group 1: Product Approval - The approval of Fluoxetine Maleate Tablets is classified as a Category 4 chemical drug, which is considered equivalent to passing the consistency evaluation according to national policies [1] - This product approval enhances the company's product line, contributing to increased market competitiveness [1]